StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$32.87−1.03 (-3.04%)

Close on Nov 17, 2026Market cap $1.83BP/E –Yield –

Maze Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Maze Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$106.54M. For fiscal 2025 it was -$111.94M, down 247.4% from the year before.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$111.94M-247.4%
FY2024Dec 31, 2024$75.95M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.05M–
Q1 FY2026Mar 31, 2026-$39.11M–
Q4 FY2025Dec 31, 2025-$27.73M–
Q3 FY2025Sep 30, 2025-$24.64M–
Q2 FY2025Jun 30, 2025-$30.05M-120.7%
Q1 FY2025Mar 31, 2025-$29.52M–
Q4 FY2024Dec 31, 2024-$22.45M–
Q3 FY2024Sep 30, 2024-$23.21M–
Q2 FY2024Jun 30, 2024$145.05M–
Q1 FY2024Mar 31, 2024-$23.44M–

More Maze Therapeutics figures

See a number that looks wrong?